Report it or Lose It - CMS Further Tightens Rules Requiring Items to be on the Medicare Cost Report

February 11, 2016 Alerts and Newsletters

As hospitals with a September 30th fiscal year end rapidly approach their Medicare cost report filing deadline, their finance departments should take heed as CMS continues to tighten the requirements for how costs may be reimbursed by Medicare.

In the November issuance of the final 2016 Outpatient Prospective Payment System (OPPS) update rule, CMS attempted to limit the seemingly endless litigation over whether the Provider Reimbursement Review Board (PRRB) has jurisdiction over costs not claimed on a provider's cost report. Specifically, CMS has imposed a new standard that essentially mandates that an item must be claimed on a provider's cost report in order to be reimbursed. In other words, if an item is not claimed on the cost report, then no payment is allowable for that item, either by the Medicare Administrative Contractor (MAC) in a Notice of Program Reimbursement (NPR) or by any reviewing body such as the PRRB or a court.

Disputes over non-claimed items typically arise when a hospital has failed to include certain Medicaid eligible days in its Disproportionate Share Hospital (DSH) payment calculation because such days were discovered only after the cost report was filed and an NPR was issued. Under CMS's new regulation, a provider must either claim the item on the cost report or self-disallow the item by observing the requirements for protesting items.

The new regulation sets forth the requirements for properly protesting an item. The provider must report the protested item on the appropriate "protested amount" line of the cost report; attach a worksheet explaining why a self-disallowance is necessary; and, describe how it determined the estimated amount for each self-disallowed item.

However, all hope is not lost for providers who fail to include a particular item on a given cost report. Items not included on a cost report still might be allowed if the provider files an amended cost report or seeks a reopening within three years of filing the cost report. Although these two avenues are purely within the discretion of the MAC and offer no appeal rights for the provider, it is heartening that CMS recognizes that some Medicaid days (which are crucial to the Medicare DSH calculation) cannot be known at the time of filing the cost report. CMS has instructed MACs that they must accept one amended cost report that is submitted within 12 months of the cost report due date solely to update Medicaid eligible days after the hospital receives updated Medicaid eligibility information from the state. When the provider submits an amended cost report in such an instance, it must include an explanation of why the days could not be verified in the initial cost report. CMS also notes that a MAC should accept an amended cost report that reflects GME and IME adjustments from a prior or penultimate year that were made after the cost report was filed.

These revisions to the provider cost reporting requirements and appeals process place a further onus on providers to identify and preserve appealable issues as part of the cost report. Rather than engaging legal counsel to prosecute appeals at the PRRB and argue that the Board has jurisdiction over unclaimed items, providers may well be advised to get counsel involved at the time of preparing cost reports in order to preserve rights to Medicare reimbursement.

If you wish to discuss in more detail please contact your regular Verrill Dana attorney or Will Stiles (207-253-4966 or [email protected]), or Gary Rosenberg (617-274-2846 or [email protected]).
___________________________________________________________________
This communication is intended for general information purposes and as a service to clients and friends of Verrill Dana, LLP. This publication, which may be considered advertising under the ethical rules of certain jurisdictions, should not be construed as legal advice or a legal opinion on any specific facts or circumstances, nor does it create attorney-client privilege.

Firm Highlights

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

News

Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

News

38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...

News

Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...

Publication/Podcast

EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...

Publication/Podcast

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Publication/Podcast

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...

Publication/Podcast

FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...